WE CLAIM:

- An in vitro method for producing dendritic cells from pluripotential cells, comprising contacting the pluripotential cells with a factor for a time sufficient for the pluripotential cells to mature and express characteristics of dendritic cells.
- 5 2. The method of claim 1, wherein the pluripotential cells are CD14 positive mononuclear pluripotential cells.
 - The method of claim 1, wherein the pluripotential cells are peripheral blood mononuclear cells.
 - 4. The method of claim 1, wherein the pluripotential cells are monocytes.
 - 5. The method of claim 1, wherein the factor comprises GM-CSF.
 - 6. The method of claim 5, wherein the factor further comprises a cytokine selected from the group consisting of IL-4; IL-13; IL-4 and IL-1β; IL-13 and IL-1β; IL-4 and TNF-α; IL-13 and TNF-α; IL-14, IL-1β, and TNF-α; IL-13, IL-1β, and TNF-α; IL-4 and IL-12; IL-13 and IL-12; IL-4 and stem cell factor, IL-13 and stem cell factor; IL-4 and IL-15; and IL-13 and IL-15.
 - The method of claim 5, wherein the GM-CSF is present at a concentration of between about 200 U/ml to about 2000 U/ml.
 - The method of claim 1, wherein the dendritic cells express high levels of MHC class molecules.
- 20 8. The method of claim 1, wherein the dendritic cells have the capacity to stimulating resting T cells.